Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OBX
Strong SellObsidian Therapeutics, Inc. · Healthcare · United States · $1.2B
7
StockRankGet insider-trade alerts
Q
28
V
25
M
23
P/E (TTM)
—
ROE
—
D/E
0.1x
Dividend %
—
Loading 1Y...
PRICE (1Y)-6.9%
Close
$16.30
RSI (14)
12.0
SCORE BREAKDOWN
Quality
28
ROIC
-144.3%4.4
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%40.1
FCF/Assets
-102.1%2.1
Piotroski
239.9
Int. Cover
—N/A
D/E Ratio
0.07x68.0
Current Ratio
4.21x65.5
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-2.8x25.0
P/FCF
—N/A
P/B
-1.4x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
23
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-43%10.9
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.2B
P/E (Forward)
-8.6x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OBX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OBX | Obsidian Therapeutics, Inc.(you) | $1.2B | 7 | Strong Sell |
| SANA | Sana Biotechnology, Inc. | $1.1B | 8 | Strong Sell |
| ODTX | Odyssey Therapeutics, Inc. | $1.2B | 5 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | 9 | Strong Sell |
| SPTX | Seaport Therapeutics, Inc. | $1.3B | 9 | Strong Sell |
| LTGO | Latigo Biotherapeutics, Inc. | $1.4B | 8 | Strong Sell |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.2B | 12 | Strong Sell |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.5B | 6 | Strong Sell |
| OLMA | Olema Pharmaceuticals, Inc. | $913M | 5 | Strong Sell |
| ANNX | Annexon, Inc. | $959M | 10 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%